Bryhali Approved to Treat Plaque Psoriasis
November 6, 2018 – The U.S. FDA has approved Bryhali™ (halobetasol propionate) Lotion 0.01%, manufactured by Ortho Dermatologics. A corticosteroid, Bryhali is indicated as a topical treatment for plaque psoriasis in adults.
Although the active ingredient, halobetasol, is available in other topical formulations, Bryhali offers a high potency topical formulation that can be used for up to eight weeks. Most other similar products can only be used for two to four weeks. In clinical studies, 38% of patients achieved clear to almost clear skin after using Bryhali for eight weeks.
Recommended dosing is a thin layer of Bryhali applied to affected areas of the skin once daily. Treatment may continue for up to eight weeks, but should be discontinued sooner if the patient achieves control of their condition.
Bryhali has launched at a wholesale acquisition cost (WAC) of $400 per 100g tube.